Division of Pediatric Hematology and Oncology

The research interests of Aleksandar Babic, M.D., are focused on the evaluation of outcomes of umbilical cord blood (UCB) transplantation. Babic was recruited as Medical Director at St. Louis Cord Blood Bank and subsequently became medical director the con combined Saint Louis University Cellular Therapy Laboratory.

The research interests of Deepika Bhatla, M.D., include the treatment of acute leukemias and lymphomas (with particular reference to the influence of host polymorphisms on disease incidence and response to treatment) and stem cell transplantation with a special interest in umbilical cord blood transplantation. She serves as institutional co-principal investigator for the Primary Immune Deficiencies Treatment Consortium (PIDTC), including Protocol #6901 ("A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders") and as institutional Principal Investigator for the National Marrow Donor Program protocol 10-CBA ("A multicenter access and distribution protocol for unlicensed and cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematological malignancies and other indications"). She is also the institutional PI for the multicenter trial entitled "A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Non-Malignant Disease Using a Reduced-Intensity Preparatory Regimen."

Lily Dolatshahi, M.D.,'s major clinical research interests include participation in a clinical trial designed to improve the outcome of sickle cell disease. She was co-investigator for an ongoing clinical trial, "Adjuvant low dose rituximab for the patients with severe TTP."  

William S. Ferguson, M.D.,'s research interests include participation in Children's Oncology Group studies treating newly diagnosed osteosarcoma, Ewing sarcoma, and other soft tissue sarcomas; clinical trials evaluating new antineoplastic agents in the treatment of solid tumors, in particular neuroblastoma; and utilizing genetic profiling of high-risk tumors to guide therapy. He is the institutional Principal Investigator for the Children's Oncology Group, the Beat Childhood Cancer Research Consortium, and the Pediatric Transplant and Cellular Therapy Consortium.

Major clinical research interests include continued participation in clinical trials designed to improve drug treatment of children with bleeding disorders and participation in clinical trials conducted through the Children's Oncology Group.

Clinical research interests include stem cell transplantation and improving the utilization of palliative and end-of-life care in children with chronic, complex, and life-limiting illnesses. She is medical director for CGCH's palliative care program, Footprints.

Cupit-Link's reserach interests centers around the acute and long-term toxicities of cancer-directed therapies, including chemotherapy and novel immunotherapies. 

The focus of Puetz's clinical research has been in pediatric hemostasis and thrombosis, with investigative studies into hemophilia and other bleeding disorders, fresh frozen plasma, and thrombosis in children. He has participated in government and industry sponsored research for over 20 years. He also completed several investigator-initiated trials. Current endeavors include data and submission trials for HRSA , CDC, and the American Thrombosis and Hemostasis Network (ATHN) while he  continues to investigate hemophilia carriers and children with pulmonary embolism.

Rocco's research interests include basic science research and translational research involving cellular therapy and oncolytic virotherapy in pediatric brain tumors. Her overarching goal is to continue to further identify the barriers and challenges related to the treatment of pediatric brain tumors. Her passion to address the unmet need of less toxic and more effective treatments for pediatric brain tumors through the development of clinical trials.

Truscott has a focus on liquid tumors (leukemia/lymphoma) and hematopoietic stem cell transplant/cellular therapy. She is actively involved in clinical research studies here at Cardinal Glennon Children's Medical Center. She also works as the medical director of Project Beacon, working to optimize the ordering of essential medications for the treatment of childhood cancer. 

• Puetz J, Wurm F. Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing Processes 2019, 7(8), 476

• Puetz J, Cheng D. Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset. Haemophilia 2021; 27: 6: 1045-1050.

• Puetz J, Hu B. Factor Activity Levels and Bleeding Scores in Pediatric Hemophilia Carriers Enrolled in the ATHNdataset. Pediatr Blood Cancer 2023; 70: 30644.

• Puetz J. Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus. Front Med 2023: 10;12569

• Puetz J, Kumanan K, Zhang Z. Is Confirmatory Testing Still Necessary to Diagnose Von Willebrand Disease? Blood Vessels, Thrombosis and Hemostasis 2024; 1

• Puetz J. Hemophilia Gene Therapy: Another Blessing or Another Curse?. Missouri Medicine 2024; 121: 231-234.

• Cupit-Link M, Hagiwara K, Nagy M, et al. Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma [published correction appears in N Engl J Med. 2024 Oct 17;391(15):1464. doi: 10.1056/NEJMx240007.]. N Engl J Med. 2024;391(7):659-661. doi:10.1056/NEJMc2403316

• Ligon JA, Cupit-Link MC, Yu C, et al. Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance. Transplant Cell Ther. 2024;30(8):737-749. doi:10.1016/j.jtct.2024.06.006

• Cupit-Link M. It Mattered Later: A Patient-Turned-Doctor's Perspective on Fertility Loss. J Clin Oncol. 2024;42(27):3257-3258. doi:10.1200/JCO.24.00491

• Cupit-Link M, Khan R, Pappo A, Helmig S. Immune-related Adverse Events from Immune Checkpoint Inhibitors in Pediatric Patients: A Literature Review and Case Series. EJC Paediatric Oncology. 2023; 2: 100117. Published 2023 Dec. https://doi.org/10.1016/j.ejcped.2023.100117.

• Cupit-Link M, Federico SM. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction. Cancers (Basel). 2023;15(18):4609. Published 2023 Sep 18. doi:10.3390/cancers15184609

• Cupit-Link MC. The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children. ClinicalTrials.gov Identifier: NCT04678947. 2021.  

• Blackall D, Dolatshahi L. Autoimmune Hemolytic Anemia in Children: Laboratory Investigation, Disease Associations, and Treatment Strategies. J Pediatr Hematol Oncol. 2022 Apr 1;44(3):71-78. doi: 10.1097/MPH.0000000000002438. PMID: 35235549.
• Lantz M, Dolatshahi L. Hereditary Pyropoikilocytosis as a Modifier of Sickle Cell Disease Severity. J Pediatr Hematol Oncol. 2025 Apr 1;47(3):128-130. doi: 10.1097/MPH.0000000000003012. Epub 2025 Mar 3. PMID: 40036694.
• Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma [published online ahead of print, 2020 May 11]. Int J Cancer. 2020;10.1002/ijc.33044. doi:10.1002/ijc.33044
• Moskop, A., Dalrymple, A., & Dolatshahi, L. (2020). Systemic Lupus Erythematosus, Evans Syndrome, and Neurofibromatosis: An Unusual Combination in Pediatric Patient. Journal of Pediatric Hematology/oncology, 42(4), e244–e247.
• Lewis, E. C., Kraveka, J. M., Ferguson, W., Eslin, D., Brown, V. I., Bergendahl, G., … Saulnier Sholler, G. L. (2020). A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. International Journal of Cancer.
• Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL.  A Subset Analysis of a Phase II Trial Evaluating the Use of DFMO as Maintenance Therapy for High-Risk Neuroblastoma. Int J Cancer 2020; 147(11):3152-3159.
• Babic A, Buchanan P, Gill A, Bloomquist J, Regan D, Bhatla D, Ferguson W. Analysis of Outcomes of Single-Unit Cord Blood Transplantation with Umbilical Cord Blood Units Processed with Two Different Red Blood Cell Sedimentation Reagents. Transfusion 2021; 61(6):1856-1866.
• Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 Dec 1;81(23):5818-5832.
• Kraveka JM, Lewis EC, Bergendahl G, Ferguson W, Oesterheld J, Kim E, Nagulapally AB, Dykema KJ, Brown VI, Roberts WD, Mitchell D, Eslin D, Hanson D, Isakoff MS, Wada RK, Harrod VL, Rawwas J, Hanna G, Hendricks WPD, Byron SA, Snuderl M, Serrano J, Trent JM, Saulnier Sholler GL. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Nov;5(11):e1616. doi: 10.1002/cnr2.1616. Epub 2022 Mar 31. PMID: 35355452; PMCID: PMC9675391.
• Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK. A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clin Cancer Res. 2022 Sep 15;28(18):3950-3957. doi: 10.1158/1078-0432.CCR-22-1169. PMID: 35833850; PMCID: PMC9481695.
  Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, Beeravally Nagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 1;153(5):1026-1034. doi: 10.1002/ijc.34569. Epub 2023 May 29. PMID: 37246577.
• Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024 Jan 1;42(1):90-102. doi: 10.1200/JCO.22.02875. Epub 2023 Oct 26. PMID: 37883734; PMCID: PMC10730038.
• Saulnier Sholler GL, Bergendahl C, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, RawwasJ, Roberts W, Eslin D, Oesterheld J, Wada RK. Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers: A Beat Childhood Cancer Research Consortium trial.  Genome Med. 2024 Feb 12;16(1):28. doi: 10.1186/s13073-024-01297-5. PMID: 38347552; PMCID: PMC10860258.
• Ferguson, WS.  The fault…is not in our stars, but in ourselves. J Pediatr 2020 Jan; 216:1.
• Ferguson, WS. A better way to detect iron deficiency? J Pediatr 2021 Dec; 239:2.
• Ferguson, WS.  Neurodevelopmental Consequences of Neonatal Thrombocytopenia. J Pediatr 2023; 258:113555.
• Ferguson, WS. Preventing Thrombosis in Children with MIS-C. J Pediatr 2023 262:113766.
• Ghajar-Rahimi G, Kang KD, Totsch SK, Gary S, Rocco A, Blitz S, Kachurak K, Chambers MR, Li R, Beierle E, Bag AK, Johnston J, Markert J, Bernstock JD, Friedman GK. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacol Ther. 2022
• Jones A, Rocco A, Lamb LS, Friedman GK, Hjelmeland AB. Regulation of NKG2D stress            ligands and its relevance in cancer progression. Cancers. 2022.
• Kang KD, Bernstock JD, Totsch SK, Gary S, Rocco A, Nan L, Li R, Bae S, Etminan T, Mott BT, Han X, Eisemann T, Wechsler-Reya RJ, Beierle E, Whitley R, Gillespie GY, Markert JM, Friedman GK. Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1. Clinical Cancer Research. 2023
•  Truscott J, Wang V. Fleisher & Ludwig's 5-Minute Pediatric Emergency Medicine Consult, 3rd edition. “Cancer Treatment Complications.”. pending publication
•  Zheng R, Fuda F, Gagan JR, Weinberg OK, Koduru P, Cantu M, Ludwig K, Truscott JM, Collins R, Chung S, Madanat YF, Chen W. Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype. Leuk Res Rep. 2023 Dec 31;21:100410. doi: 10.1016/j.lrr.2023.100410. PMID: 38273970; PMCID: PMC10808966.
• Truscott J, Guan X, Fury H, Atagozli T, Metwali A, Liu W, Li Y, Li RW, Elliott DE, Blazar BR, Ince MN. After Bone Marrow Transplantation, the Cell-Intrinsic Th2 Pathway Promotes Recipient T Lymphocyte Survival and Regulates Graft-versus-Host Disease. Immunohorizons. 2023 Jun 1;7(6):442-455. doi: 10.4049/immunohorizons.2300021.
•  Li Y, Liu W, Guan X, Truscott J, Creemers JW, Chen HL, Pesu M, El Abiad RG, Karacay B, Urban JF Jr, Elliott DE, Kaplan MH, Blazar BR, Ince MN. STAT6 and Furin Are Successive Triggers for the Production of TGF-β by T Cells. J Immunol. 2018 Nov 1;201(9):2612-2623. doi: 10.4049/jimmunol.1700808. Epub 2018 Sep 2
• Li Y, Guan X, Liu W, Chen HL, Truscott J, Beyatli S, Metwali A, Weiner GJ, Zavazava N, Blumberg RS, Urban JF Jr, Blazar BR, Elliott DE, Ince MN. Helminth-Induced Production of
  TGF-β and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. J Immunol. 2018 Nov 15;201(10):2910-2922. doi: 10.4049/jimmunol.1700638. Epub 2018 Oct 5
• Metwali A, Thorne PS, Ince MN, Metwali N, Winckler S, Guan X, Beyatli S, Truscott J, Urban JF Jr, Elliott DE. Recirculating Immunocompetent Cells in Colitic Mice Intensify Their Lung Response to Bacterial Endotoxin. Dig Dis Sci. 2018 Jul 11. doi: 10.1007/s10620-018-5196-z. PMID: 30022451
• Zhang M, Truscott J, Davie J. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer. 2013 Nov 27;12(1):150. PubMed PMID: 24279793; PubMed Central PMCID: PMC387906

• Oesterheld JE, Bergendahl G, Berry DA, Lorenzi E, Clinch T, Kraveka JM, Ferguson W, Brown VI, Eslin D, Hanson D, Harrod VL, Isakoff M, Mitchell D, Wada R, Zage PE, Saulnier Sholler GL. Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.  American Society of Clinical Oncology Annual Meeting, June 2022.
• Oesterheld JE, Bergendahl G, Berry DA, Lorenzi E, Clinch T, Kraveka JM, Ferguson W, Brown VI, Eslin D, Hanson D, Harrod VL, Isakoff M, Mitchell D, Wada R, Zage PE, Saulnier Sholler GL. Comparison of event free survival (EFS) in high-risk neuroblastoma (HRNB) patients receiving enflornithine (DFMO) maintenance to an external control immunotherapy study database.  International Society of Paediatric Oncology (SIOP) annual meeting, Sept-Oct 2022.
• Saulnier Sholler GL, Kraveka J, Bergendahl G, Lewis E, Ferguson  W, Nagulapally A, Dykema K, Brown V, Isakoff M, Junewick  J, Mitchell D, Eslin D, Harrod V, Roberts W, Oesterheld J, Wada R, Rawwas J, Pastakia D, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna G, Enriquez D, Izatt T, Halperin R, Byron S, Hendricks W, Trent J. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. American Association for Cancer Research (AACR) Annual Meeting April 2023.
• Kraveka J, Ferguson W, Bergendahl G, Lewis EC, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Byron SA, Hendricks WPD, Trent JM, Saulnier Sholler GL. Molecular-guided therapy for the treatment of relapsed neuroblastoma: A Beat Childhood Cancer Research Consortium Trial. Advances in Neuroblastoma Research Annual Meeting May 2023.
• Oesterheld J, Saulnier Sholler G, Ferguson W, Bergendahl G, Kraveka JM, Clinch T, Lorenzi E, Berry DA, Wada RK, Isakoff MS, Eslin DE, Brown VI, Zage P, Harrod VL, Mitchell DS, Hanson D. Confirmation of Event Free Survival (EFS) in High-Risk Neuroblastoma (HRNB) Patients Receiving Eflornithine (DFMO) Maintenance Treatment based on a Retrospective, Blinded Independent Central Review (BICR) of Imaging during Long-Term Follow-Up. American Society of Clinical Oncology Annual Meeting, June 2023.
• Bergendahl G, Kraveka J, Ferguson W, Oesterhald J, Clinch T, Gullo KL, Staines H, Sholler G.  EFS and OS in Study 3b Patients with High-Risk Neuroblastoma Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls.  Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference September 2023.
• Kraveka J, Oasterheld J, Ferguson W, Bergendahl G, Clinch T, Staines H, Sholler G.  MICE Sensitivity Analysis of Event Free Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls.  International Society of Paediatric Oncology (SIOP) annual meeting, October 2023.
• Kraveka J, Berg A, Bergendahl G, Ferguson W, Ginn K, Mitchell D, Wada R, Brown V,  Isakoff M, Moore A, SaulnierSholler G. End of Induction Response Correlates with Clinical Outcome in High-Risk Neuroblastoma Patients. Annual meeting of American Society of Pediatric Hematology/Oncology, Seattle, WA, April 2024
• Clinch T, Ferguson W, Kraveka J, Staines H, Bergendahl G, Berg A, SaulnierSholler G. Assessment of Household Poverty Exposure in Patients with HRNB Receiving DFMO Maintenance Treatment. Annual meeting of American Society of Pediatric Hematology/Oncology, Seattle, WA, April 2024.
• Saulnier Sholler GL, Ferguson W, Bergendahl G, Clinch T, Kraveka JM. Survival Outcomes in High-Risk Neuroblastoma (HRNB) Patients in Remission after Relapsed or Refractory Treatment Receiving Eflornithine (DFMO) Maintenance. Submitted to American Society of Clinical Oncology Annual Meeting, June 2024.
• Bergendahl G, Steinbrecher J, Smith L, Lincoln J, Moore A, Clinch T, Ferguson W, Kraveka JM, Saulnier Sholler G. Clinical Administration of DFMO (Eflornithine) is Flexible in Pediatric Patients with HRNB.  Submitted to Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference September 2024.
• Kraveka J, Ferguson W, Bergendahl G, Clinch T, Moore A, Eslin D, Brown V, Roberts W, Wada R, Mitchell D, Zage P, Rawwas J, Saulnier Sholler G. Survival Outcomes in Patients with High-Risk Neuroblastoma (HRNB) in Remission After Relapsed or Refractory Treatment Receiving Eflornithine (DFMO) Maintenance. Submitted to International Society of Paediatric Oncology (SIOP) annual meeting, October 2024.
• Moore A, Lincoln J, Bergendahl G, Treadway S, Halley N, Caran E, Ambar N, Nagulapally A, Draveka J, Ferguson W, Saulnier Sholler G. Use of Eflornithine (DFMO) in High Risk Neuroblastoma (HRNB) Patients from Brazil: A Promising Experience for the Future. Submitted to International Society of Paediatric Oncology (SIOP) annual meeting, October 2024.
• Kraveka JM, Ferguson W, Bergendahl G, Clinch T, Moore A, Lincoln J, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Harrod VL, Mitchell DS, Saulnier Sholler G. Survival Outcomes in Patients with High-Risk Neuroblastoma (HRNB) Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls: Subgroup Analysis on Geographic Region. Oral presentation at the International Society of Paediatric Oncology (SIOP) annual meeting, October 2024.
• Saulnier Sholler G, Ferguson W, Bergendahl G, Clinch T, Staines H, Berg A, Kraveka JM. Assessment of Household Poverty Exposure in Patients with High-Risk Neuroblastoma (HRNB) Receiving Eflornithine (DFMO) Maintenance Treatment. Submitted to International Society of Paediatric Oncology (SIOP) annual meeting, October 2024.
• Bergendahl G, Kraveka JM, Ferguson W, Brown V, Huang M, Steinbrecher J, Moore A, Lincoln J, Salnier Sholler, G.  Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine (DFMO) in Pediatric Solid Tumors.  Submitted to the American Society of Pediatric Hematology-Oncology annual meeting, May 2025.
• Kraveka JM, Bergendahl G, Ferguson W, Berg A, Wada RK, Tiera P, Bielamowicz K, Michon B, Alva E, Steinbrecher J, Moore A, Saulnier Sholler G.  Safety of Naxitimab + Granulocyte Macrophage Colony Stimulating (GM-CSF) in Combination with Induction Chemotherapy in High-Risk Neuroblastoma (HRNB). Submitted to the American Society of Pediatric Hematology-Oncology annual meeting, May 2025.
• Bergendahl G, Ferguson W, Kraveka JM, Moore A, Clinch T, Saulnier Sholler G.  Survival Outcomes in Patients with HRNB in Remission 7 Years After Starting DFMO Maintenance Therapy. Submitted to the American Society of Pediatric Hematology-Oncology annual meeting, May 2025.
• Bergendahl G, Kraveka JM, Ferguson W, Brown V, Huang MAC, Steinbrecher J, Moore A, Lincoln J, Saulnier Sholler G.  Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine (DFMO) in Pediatric Solid Tumors.  Submitted to the Advances in Neuroblastoma Research Association meeting, May 2025.
• Kraveka JM, Bergendahl G, Ferguson W, Berg A, Wada RK, Tiera P, Bielamowicz K, Michon B, Alva E, Steinbrecher J, Moore A, Saulnier Sholler G.  Safety of Naxitimab + Granulocyte Macrophage Colony Stimulating (GM-CSF) in Combination with Induction Chemotherapy in High-Risk Neuroblastoma (HRNB). Submitted to the Advances in Neuroblastoma Research Association meeting, May 2025.
• Saulnier Sholler G, Lincoln J, Bergendahl G, Ferguson W, Brown V, Steinbrecher J, Moore A, Kraveka JM.  Safety and ALK Inhibitors in Combination with Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB). Submitted to the Advances in Neuroblastoma Research Association meeting, May 2025.
• Berg A, Kraveka J, Bergendahl G, Gerguson W, Ginn K, Mitchell D, Wada RK, Brown VI, Isakoff MS, Moore A, Saulnier Sholler G.  End-of-Induction Response as a Surrogate Endpoint for Overall Survival in High-Risk Neuroblastoma.  Submitted to the Advances in Neuroblastoma Research Association meeting, May 2025.
• Ferguson W, Kraveka JM, Bergendahl G, Moore A, Clinch T, Saulnier Sholler G.  Survival Outcomes in Patients with High-Risk Neuroblastoma on Eflornithine (DFMO) Maintenance: Matched External Control Analysis at 7-Year Follow-Up. Submitted to the Advances in Neuroblastoma Research Association meeting, May 2025.
• Bergendahl G, Steinbrecher J, Smith L, Treadway S, Kraveka JM, Ferguson W, Brown V, Saulnier Sholler G.  Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine (DFMO) in Pediatric Solic tumors.  Submitted to Association of Pediatric Hematology/Oncology Nurses (APHON) Annual Conference September 2025.
• Harrod V, Brown V, Ferguson W, Kraveka J, Mitchell M, Eslin D, Wada R, Roberts W, Bergendahl G, Lincoln J, Steinbrecher J, Moore A, Treadway S, Gollamudi VRM, Bansai S, Ambar N, Caran E, Saulnier Sholler G.  Impact of Eflornithine Maintenance Therapy on Survival in high Risk Neuroblastoma Patients from China, India and Brazil. Submitted to the International Society of Paediatric Oncology (SIOP) annual meeting, October 2025.
• Moore A, Nagulapally A, Kraveka J, Ferguson W, Brown V, Harrod V, Eslin D, Glover J, Mitchell M, Michael M, Hanna G, Dovat S, Saulnier Sholler G.  Pediatric Consortium Development and Oversight of an International Molecular Tumor Board. Submitted to the International Society of Paediatric Oncology (SIOP) annual meeting, October 2025.
• Saulnier Sholler G, Lincoln J, Bergendahl G, Ferguson W, Brown V, Moore A, Steinbrecher J, Kraveka J.  Safety of Alk Inhibitors in Combination with Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB). Submitted to the International Society of Paediatric Oncology (SIOP) annual meeting, October 2025.

Deepika Bhatla, M.D.

Leili Dolatshahi, M.D.

• “Severe Warm Autoimmune Hemolytic Anemia in a 7-month-old Infant Associated With a Mycoplasma Pneumoniae Infection” (Journal of Pediatric Hematology Oncology, November 2017
• SCHOLARSHIP
• Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE Study), Site Investigator (July 2017 – now)
•  Sickle cell and hemoglobinopathies of Illinois State, Principal Investigator (July 2017 – now)
• Missouri Department of Health and Senior Services Pediatric Hemoglobinopathy Resource Center Service, Principal Investigator (June 2017 – now)

William Ferguson, M.D.

• Pediatric Research Colloquium: “DFMO (Eflornithine) as Maintenance
  Therapy for High-Risk Neuroblastoma”
• Introduction to Academic Medicine: “Informed Consent and the Ethics of Clinical Research”

Maggie Cupit-Link, M.D.

• Treatment of High-Risk Neuroblastoma Using Dinutuximab Chemoimmunotherapy in All Cycles of Induction. Advances in Neuroblastoma. Amsterdam, Netherlands. 2023     
• Predictors of Nausea During Early Treatment in Children with Acute Lymphoblastic Leukemia. American Society of Pediatric Hematology Oncology. Fort Worth, TX. 2023     
• Treatment of High-Risk Neuroblastoma Using Dinutuximab Chemoimmunotherapy in All Cycles of Induction. American Society of Pediatric Hematology Oncology. Fort Worth, TX. 2023                 

 Abbey Rocco, M.D.

•  Rocco, A. Targeting Pediatric Malignant Brain Tumors with Chlorotoxin Chimeric Antigen Receptor Gamma Delta T Cells. UAB Department of Pediatric Hematology Oncology Division Research Presentation. Birmingham, AL December 07, 2021
   
• Rocco, A. Targeting Pediatric Malignant Brain Tumors with Chlorotoxin Chimeric Antigen Receptor Gamma Delta T Cells. UAB Department of Pediatric Hematology Oncology Division Research Presentation. Birmingham, AL August 09, 2022
   
• Rocco, A. Targeting Pediatric Malignant Brain Tumors with MGMT modified Gamma Delta T Cells. UAB Department of Pediatric Hematology Oncology Division Research Presentation. Birmingham, AL March 21, 2023                                             

John Puetz M.D.

• Hemophilia Carrier, Regional Meeting, New Orleanes, 2024
• Hemophilia Gene Therapy, Grand Rounds. Columbia, Missouri. 2023
• Hemophilia Gene Therapy, Project ECHO. Houston, Texas. 2022
• Hemostasis Update, Grand Rounds, St. Louis, Missouri. 2021
• Microbleeds, Regional Meeting. Lansing, Michigan. 2020